Patients with deadly glioblastomas who received high doses of radiation that hit a portion of the brain that harbors neural stem cells had double the progression-free survival time as patients who had lower doses or no radiation targeting the area, a study from the Radiation Oncology Department at

read more>>

LOS ANGELES -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indicationsThe Company has enrolled its first patien

read more>>

WASHINGTON -- Anne Feeley, a 56-year-old mother and brain cancer survivor, completed her journey across America today, cycling 3,708 miles, to raise awareness and money for brain cancer research and patient careFeeley pedaled the last 6.5 miles of her journey from Hains Point, VA to cross the fini

read more>>

ImmunoCellular Therapeutics Ltd. on Friday said that its lead experimental cancer vaccine had been granted orphan drug status by the U.S. Food and Drug Administration, which provides some advantages in commercializing the treatmentThe Los Angeles biotech said it will now be eligible for grant fund

read more>>

TUSTIN, CA -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today will present tumor response and progression-free survival data from three clinical Phase II A

read more>>

CHICAGO -- Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in

read more>>

CHICAGO -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that interim results from a Phase 2b study evaluating rindopepimut (formerly PF-04948568 or CDX-110) in newly-diagnosed glioblastoma multiforme (GBM) patients were presented at the 46th Annual Meeting of the American Society of R

read more>>

LOS ANGELES, CA -- ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that data from a recent clinical trial of ICT-107, the company’s dendritic cell based cancer vaccine candidate for the treatment of

read more>>

NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX), an antibody-based combination immunotherapy company, today announced that four presentations on clinical data from three of its product candidates will be made at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO

read more>>

CLEARWATER, Fla. -- Each day in the United States, 482 people are diagnosed with a brain tumorFor these 482 people, not many treatments exist. With the current treatments available, only 5% of those diagnosed with a Glioblastoma Multiform will survive more than 5 years. Only two new treatments ha

read more>>